Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 17 Ovarian Neoplasms 16 Fallopian Tube Neoplasms 12 Neoplasm Metastasis 10 Triple Negative Breast Neoplasms 7 Prostatic Neoplasms 7 Neoplasms 7 Endometrial Neoplasms 6 Small Cell Lung Carcinoma 5 Pancreatic Neoplasms 5 Parkinson Disease 4, Autosomal Dominant Lewy Body 4 Neuroendocrine Tumors 3 Metastatic Castration-resistant Prostate Cancer 3 Lymphoma, Non-Hodgkin 3 Lung Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Urinary Bladder Neoplasms 2 Stomach Neoplasms 2 Solid Tumors 2 Sarcoma 2 Recurrence 2 Pheochromocytoma 2 Paraganglioma 2 Osteosarcoma 2 Neuroblastoma 2 Multiple Myeloma 2 Medulloblastoma 2 Glioma 2 Glioblastoma 2 Ependymoma 2

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Solid Neoplasms × olaparib × 90 days × Clear all

NCT03742895 2026-05-15

MK-7339-002

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting

Advanced Solid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡